Irinotecan
Nonpapillary Renal Cell Carcinoma
Explore 112 assets in Nonpapillary Renal Cell Carcinoma →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02210117CT.gov Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT01684397CT.gov Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | — | Active Not Recruiting | — | — | — |
NCT01727089CT.gov Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT01243359CT.gov Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | — | Completed | — | — | — |
NCT01198158CT.gov Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | — | Terminated | — | — | — |
NCT00378703CT.gov Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT00324870CT.gov Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | — | Completed | — | — | — |
NCT00112840CT.gov CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | — | Completed | — | — | — |
NCT00126503CT.gov Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | — | Completed | — | — | — |
NCT00193258CT.gov Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nonpapillary Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | M.D. Anderson Cancer Center | P3 | B · 63 |
| Girentuximab | Massachusetts General Hospital | P3 | BB |
| Clostridium Butyricum Miyairi 588 | City of Hope Medical Center | P3 | BB |
| Pazopanib | Academic and Community Cancer Research United | P4 | BB |
| Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer | Regeneron Pharmaceuticals | P2 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P3 | BB |
| Cabozantinib | SWOG Cancer Research Network | P3 | BB |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
| Ipilimumab | SWOG Cancer Research Network | P3 | B |
+42 more in the Nonpapillary Renal Cell Carcinoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GirentuximabMassachusetts General HospitalBB
- Clostridium Butyricum Miyairi 588City of Hope Medical CenterBB
- PazopanibAcademic and Community Cancer Research UnitedBB
- Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, DimerRegeneron PharmaceuticalsBB
- NivolumabFred Hutchinson Cancer CenterBB
Citation
Floatz Terminal. Irinotecan in Nonpapillary Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-nonpapillary-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →